Medifast, Inc.

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, ROL has a market cap of 27.5B. Regarding current trading prices, MED is priced at $10.98, while ROL trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas ROL's P/E ratio is 52.29. In terms of profitability, MED's ROE is -0.09%, compared to ROL's ROE of +0.37%. Regarding short-term risk, MED is less volatile compared to ROL. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check ROL's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, SCI has a market cap of 12B. Regarding current trading prices, MED is priced at $10.98, while SCI trades at $86.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas SCI's P/E ratio is 22.73. In terms of profitability, MED's ROE is -0.09%, compared to SCI's ROE of +0.34%. Regarding short-term risk, MED is less volatile compared to SCI. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check SCI's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, BFAM has a market cap of 4.5B. Regarding current trading prices, MED is priced at $10.98, while BFAM trades at $81.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas BFAM's P/E ratio is 24.31. In terms of profitability, MED's ROE is -0.09%, compared to BFAM's ROE of +0.14%. Regarding short-term risk, MED is less volatile compared to BFAM. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check BFAM's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, FTDR has a market cap of 4.3B. Regarding current trading prices, MED is priced at $10.98, while FTDR trades at $60.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas FTDR's P/E ratio is 17.82. In terms of profitability, MED's ROE is -0.09%, compared to FTDR's ROE of +1.01%. Regarding short-term risk, MED is less volatile compared to FTDR. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check FTDR's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, HRB has a market cap of 3.9B. Regarding current trading prices, MED is priced at $10.98, while HRB trades at $31.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas HRB's P/E ratio is 7.25. In terms of profitability, MED's ROE is -0.09%, compared to HRB's ROE of -1.66%. Regarding short-term risk, MED is less volatile compared to HRB. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check HRB's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, CVSA has a market cap of 3.8B. Regarding current trading prices, MED is priced at $10.98, while CVSA trades at $110.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas CVSA's P/E ratio is 16.27. In terms of profitability, MED's ROE is -0.09%, compared to CVSA's ROE of +0.18%. Regarding short-term risk, MED is less volatile compared to CVSA. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check CVSA's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, DSEY has a market cap of 2.7B. Regarding current trading prices, MED is priced at $10.98, while DSEY trades at $8.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas DSEY's P/E ratio is -14.47. In terms of profitability, MED's ROE is -0.09%, compared to DSEY's ROE of -0.23%. Regarding short-term risk, MED is more volatile compared to DSEY. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check DSEY's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, MCW has a market cap of 2.3B. Regarding current trading prices, MED is priced at $10.98, while MCW trades at $7.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas MCW's P/E ratio is 22.61. In terms of profitability, MED's ROE is -0.09%, compared to MCW's ROE of +0.09%. Regarding short-term risk, MED is more volatile compared to MCW. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check MCW's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, ROVR has a market cap of 2B. Regarding current trading prices, MED is priced at $10.98, while ROVR trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas ROVR's P/E ratio is 183.25. In terms of profitability, MED's ROE is -0.09%, compared to ROVR's ROE of -0.07%. Regarding short-term risk, MED is more volatile compared to ROVR. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check ROVR's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, CSV has a market cap of 802.4M. Regarding current trading prices, MED is priced at $10.98, while CSV trades at $50.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas CSV's P/E ratio is 15.57. In terms of profitability, MED's ROE is -0.09%, compared to CSV's ROE of +0.22%. Regarding short-term risk, MED is less volatile compared to CSV. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check CSV's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, EM has a market cap of 148.4M. Regarding current trading prices, MED is priced at $10.98, while EM trades at $1.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas EM's P/E ratio is -117.00. In terms of profitability, MED's ROE is -0.09%, compared to EM's ROE of -0.01%. Regarding short-term risk, MED is less volatile compared to EM. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check EM's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, WW has a market cap of 92.9M. Regarding current trading prices, MED is priced at $10.98, while WW trades at $9.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas WW's P/E ratio is 1.23. In terms of profitability, MED's ROE is -0.09%, compared to WW's ROE of -26.25%. Regarding short-term risk, MED is less volatile compared to WW. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check WW's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, RGS has a market cap of 68.5M. Regarding current trading prices, MED is priced at $10.98, while RGS trades at $27.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas RGS's P/E ratio is 0.61. In terms of profitability, MED's ROE is -0.09%, compared to RGS's ROE of +0.71%. Regarding short-term risk, MED is less volatile compared to RGS. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check RGS's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, XSPA has a market cap of 54.5M. Regarding current trading prices, MED is priced at $10.98, while XSPA trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas XSPA's P/E ratio is 21.83. In terms of profitability, MED's ROE is -0.09%, compared to XSPA's ROE of +35.63%. Regarding short-term risk, MED is less volatile compared to XSPA. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check XSPA's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, XWEL has a market cap of 6.3M. Regarding current trading prices, MED is priced at $10.98, while XWEL trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas XWEL's P/E ratio is -0.22. In terms of profitability, MED's ROE is -0.09%, compared to XWEL's ROE of +1.77%. Regarding short-term risk, MED is less volatile compared to XWEL. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check XWEL's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, MRM has a market cap of 5.8M. Regarding current trading prices, MED is priced at $10.98, while MRM trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas MRM's P/E ratio is 3.01. In terms of profitability, MED's ROE is -0.09%, compared to MRM's ROE of +1.55%. Regarding short-term risk, MED is less volatile compared to MRM. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check MRM's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, EJH has a market cap of 5.2M. Regarding current trading prices, MED is priced at $10.98, while EJH trades at $1.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas EJH's P/E ratio is -0.02. In terms of profitability, MED's ROE is -0.09%, compared to EJH's ROE of +0.01%. Regarding short-term risk, MED is less volatile compared to EJH. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check EJH's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, BYAH has a market cap of 735K. Regarding current trading prices, MED is priced at $10.98, while BYAH trades at $1.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas BYAH's P/E ratio is N/A. In terms of profitability, MED's ROE is -0.09%, compared to BYAH's ROE of -5.91%. Regarding short-term risk, MED is less volatile compared to BYAH. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check BYAH's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, TRNR has a market cap of 147.9K. Regarding current trading prices, MED is priced at $10.98, while TRNR trades at $1.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas TRNR's P/E ratio is -0.01. In terms of profitability, MED's ROE is -0.09%, compared to TRNR's ROE of -1.78%. Regarding short-term risk, MED is less volatile compared to TRNR. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check TRNR's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, IVP has a market cap of 85.8K. Regarding current trading prices, MED is priced at $10.98, while IVP trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas IVP's P/E ratio is -0.00. In terms of profitability, MED's ROE is -0.09%, compared to IVP's ROE of -5.20%. Regarding short-term risk, MED is more volatile compared to IVP. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check IVP's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, YYGH has a market cap of 23K. Regarding current trading prices, MED is priced at $10.98, while YYGH trades at $1.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas YYGH's P/E ratio is N/A. In terms of profitability, MED's ROE is -0.09%, compared to YYGH's ROE of -1.36%. Regarding short-term risk, MED is less volatile compared to YYGH. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check YYGH's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, TMX has a market cap of 0. Regarding current trading prices, MED is priced at $10.98, while TMX trades at $37.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas TMX's P/E ratio is 70.13. In terms of profitability, MED's ROE is -0.09%, compared to TMX's ROE of +0.05%. Regarding short-term risk, MED is less volatile compared to TMX. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check TMX's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, NEBCU has a market cap of 0. Regarding current trading prices, MED is priced at $10.98, while NEBCU trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas NEBCU's P/E ratio is N/A. In terms of profitability, MED's ROE is -0.09%, compared to NEBCU's ROE of -0.00%. Regarding short-term risk, MED is less volatile compared to NEBCU. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check NEBCU's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 121M. In comparison, STON has a market cap of 0. Regarding current trading prices, MED is priced at $10.98, while STON trades at $3.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -6.45, whereas STON's P/E ratio is -6.64. In terms of profitability, MED's ROE is -0.09%, compared to STON's ROE of +0.48%. Regarding short-term risk, MED is more volatile compared to STON. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check STON's competition here